What Current Evidence and Clinical Trials Tell Us The key published evidence is a 2023 Phase 2 RCT (Jastreboff et al.) showing substantial weight loss and predominantly mild-to-moderate GI side effects
Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, et al
Your SheMed clinician will guide this decision based on your progress and how well you are tolerating the current dose
Cu tr li cho cu hi ny ph thuc vo mc tiu s dng v hm lng chit xut Ginkgo Biloba c trong mi vin ca sn phm
The second lever is injection frequency, extending pen usage through off-label dosing to stretch what was a monthly supply into six or eight weeks so that the patient injects less often and pays less
Most people successfully navigate this adjustment period when they follow evidence-based management approaches and maintain realistic expectations about the timeline